Angiotensinogen promoter and angiotensinogen II receptor type 1 gene polymorphisms and incidence of ischemic stroke and neurologic phenotype in Fabry disease

Biomarkers

Volumn 18, Issue 7, 2013, Pages 595-600

  Altarescu, Gheona ^a   Haim, Shimon ^a   Elstein, Deborah ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

AGT; AGTR1; Mainz Severity Score Index; RAAS; White matter lesions

Indexed keywords

ADULT; ALLELE; ALPHA GALACTOSIDASE A GENE; ANGIOTENSINOGEN GENE; ANGIOTENSINOGEN II RECEPTOR TYPE 1 GENE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DNA POLYMORPHISM; FABRY DISEASE; FEMALE; GENE; GENOTYPE; HUMAN; INCIDENCE; MAINZ SEVERITY SCORE INDEX; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PHENOTYPE; PROMOTER REGION; SCORING SYSTEM; WHITE MATTER LESION;

ADOLESCENT; ADULT; ANGIOTENSINOGEN; BRAIN ISCHEMIA; CASE-CONTROL STUDIES; FABRY DISEASE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; PREVALENCE; PROMOTER REGIONS, GENETIC; RECEPTOR, ANGIOTENSIN, TYPE 1; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84888856956     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2013.836244     Document Type: Article

References (36)

1. Baptista MV, Ferreira S, Pinho-E-Melo T, et al. (2010). Mutations of the GLA gene in young patients with stroke: The PORTYSTROKE study - screening genetic conditions in Portuguese young stroke patients. Stroke 41:431-6.
2. Brady RO, Gal AE, Bradley RM, et al. (1967). Enzymatic defect in Fabry disease: Ceramide trihexosidase deficiency. N Engl J Med 276:1163-7.
3. Brouns R, Thijs V, Eyskens F, et al. (2010). Belgian Fabry study: Prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 41:863-8.
4. Buraczynska P, Drop A, Zaluska W, et al. (2006). Genetic polymorphisms of the renin-angiotensin system in end-stage renal disease. Nephrol Dial Transplant 21:979-83.
5. Coll E, Campos B, González-Núnéz D, et al. (2003). Association between the A1166C polymorphism of the angiotensin II receptor type 1 and progression of chronic renal insufficiency. J Nephrol 16: 357-64.
6. Cooper C, Fisher ND, Cox D, et al. (2009). Genetic polymorphisms and the risk of accelerated renal function decline in women. PLoS One 4: E4787.
7. Desnick RJ, Brady R, Barranger J, et al. (2003). Fabry disease, an underrecognized multisystemic disorder: Expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 138:338-46.
8. Dubuc V, Moore DF, Gioia LC, et al. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis 2012 Nov 17. [Epub ahead of print].
9. Germain DP. (2010). Fabry disease. Orphanet J Rare Dis 5:30. doi:10.1186/1750-1172-5-30.
10. Ginsberg L. (2006). Nervous system manifestations of Fabry disease: Data from FOS - the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry disease: Perspectives from 5 years of FOS, Chapter 23. Oxford: Oxford PharmaGenesis
11. Gormley K, Bevan S, Markus HS. (2007). Polymorphisms in genes of the renin-angiotensin system and cerebral small vessel disease. Cerebrovasc Dis 23:148-55.
12. Grewal RP. (1994). Stroke in Fabry's disease. J Neurol 241:153-6.
13. Henskens LH, Spiering W, Stoffers HE, et al. (2003). Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: first results of the Hippocates study. J Hypertens 21:81-6.
14. Henskens LH, Kroon AA, van Boxtel MP, et al. (2005). Associations of the angiotensin II type 1 receptor A1166C and the endothelial NO synthase G894T gene polymorphisms with silent subcortical white matter lesions in essential hypertension. Stroke 36:1869-73.
15. Inada Y, Tazawa S, Murakami M, Akahane M. (2001). KRH-594, a new angiotensin AT1 receptor antagonist, prevents end-organ damage in stroke-prone spontaneously hypertensive/Izm rats. Clin Exp Pharmacol Physiol 28:206-11.
16. Inada Y, Wada T, Ojima M, et al. (1997). Protective effects of candesartan cilexetil (TCV-116) against stroke, kidney dysfunction and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Clin Exp Hypertens 19:1079-99.
17. Ishigami T, Umemura S, Tamura K. (1997). Essential hypertension and 50 upstream core promoter region of human angiotensinogen gene. Hypertension 30:1325-30.
18. Kaminsky P, Noel E, Jaussaud R, et al. (2013). Multidimensional analysis of clinical symptoms in patients with Fabry's disease. Int J Clin Pract 67:120-7.
19. Katsuya T, Morishita R. (2013). Gene polymorphism of angiotensin II type 1 and type 2 receptors. Curr Pharm Des 19:2996-3001.
20. Nakase T, Mizuno T, Harada S, et al. (2007). Angiotensinogen gene polymorphism as a risk factor for ischemic stroke. J Clin NeuroSci 14: 943-7.
21. Pierre-Louis B, Kumar A, Frishman WH. (2009). Fabry disease: Cardiac manifestations and therapeutic options. Cardiol Rev 17:31-5.
22. Rolfs A, Böttcher T, Zschiesche M, et al. (2005). Prevalence of Fabry disease in patients with cryptogenic stroke: A prospective study. Lancet 366:1794-6. [Erratum. Lancet 2006;368:2210].
23. Rubattu S, Di Angelantonio E, Stanzione R, et al. (2004). Gene polymorphisms of the renin-angiotensin-aldosterone system and the risk of ischemic stroke: A role of the A1166C/AT1 gene variant. J Hypertens 22:2129-34.
24. Schmidt H, Fazekas F, Kostner GM, et al. (2001a). Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: Results of the Austrian Stroke Prevention Study. Stroke 32: 405-12.
25. Schmidt R, Schmidt H, Fazekas F, et al. (2001b). Angiotensinogen polymorphism M235T, carotid atherosclerosis, and small-vessel disease-related cerebral abnormalities. Hypertension 38:110-15.
26. Sethi AA, Nordestgaard BG, Tybjærg-Hansen A. (2003). Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arterioscler Thromb Vasc Biol 23:1269-75.
27. Sims K, Politei J, Banikazemi M, Lee P. (2009). Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 40: 788-94.
28. Smilde TD, Zuurman MW, Hillege HL, et al. (2007). Renal function dependent association of AGTR1 polymorphism (A1166C) and electrocardiographic left-ventricular hypertrophy. Am J Hypertens 20:1097-103.
29. Takami S, Imai Y, Katsuya T, et al. (2000). Gene polymorphism of the renin-angiotensin system associates with risk for lacunar infarction. The Ohasama study. Am J Hypertens 13:121-7.
30. Terryn W, Cochat P, Froissart R, et al. (2013). Fabry nephropathy: Indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 28: 505-17.
31. Tuttolomondo A, Simonetta I, Miceli S, et al. Anderson-Fabry disease: A multiorgan disease. Curr Pharm Des 2013 Feb 19. [Epub ahead of print].
32. van Rijn MJ, Bos MJ, Isaacs A, et al. (2007). Polymorphisms of the renin-angiotensin system are associated with blood pressure, atherosclerosis and cerebral white matter pathology. J Neurol Neurosurg Psychiatry 78:1083-7.
33. Viana-Baptista M. (2012). Stroke and Fabry disease. J Neurol 259: 1019-28.
34. von Sarnowski B, Putaala J, Grittner U, et al. (2013). Lifestyle risk factors for ischemic stroke and transient ischemic attack in young adults in the Stroke in Young Fabry Patients study. Stroke 44: 119-25.
35. Whybra C, Kampmann C, Krummenauer F, et al. (2004). The Mainz Severity Score Index: A new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65:299-307.
36. Wozniak MA, Kittner SJ, Tuhrim S, et al. (2010). Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 41: 78-81.